Disease modifying drugs modulate endogenous secretory receptor for advanced glycation end-products, a new biomarker of clinical relapse in multiple sclerosis
- 1 September 2014
- journal article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 274 (1-2) , 197-201
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- RAGE-Mediated Inflammation, Type 2 Diabetes, and Diabetic Vascular ComplicationFrontiers in Endocrinology, 2013
- Serum Level of Endogenous Secretory Receptor for Advanced Glycation End Products and Other Factors in Type 2 Diabetic Patients With Mild Cognitive ImpairmentDiabetes Care, 2011
- Elevated Serum Levels of Advanced Glycation End Products and their Monocyte Receptors in Patients with Type 2 DiabetesArchives of Medical Research, 2011
- S100A14 Stimulates Cell Proliferation and Induces Cell Apoptosis at Different Concentrations via Receptor for Advanced Glycation End Products (RAGE)PLOS ONE, 2011
- Chronic Mild Stress Induces Fluoxetine-Reversible Decreases in Hippocampal and Cerebrospinal Fluid Levels of the Neurotrophic Factor S100B and Its Specific ReceptorInternational Journal of Molecular Sciences, 2010
- Diagnostic potential of plasma carboxymethyllysine and carboxyethyllysine in multiple sclerosisJournal of Neuroinflammation, 2010
- Alternative splicing of the murine receptor for advanced glycation end‐products (RAGE) geneThe FASEB Journal, 2009
- Tempering the wrath of RAGE: An emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammationAnnals of Medicine, 2009
- A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane‐bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10)The FASEB Journal, 2008
- RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brainNature Medicine, 2003